Abstract 4691
Background
Acute promyelocytic leukemia (APL) is strongly related to obesity. APL patients have significantly higher body mass index (BMI) than other acute leukemia. In APL patients, BMI over 30 kg/m2 is reported to be a risk factor of all trans retinoic acid (ATRA) induced differentiation syndrome (DS), and associated with inferior disease free survival (DFS) and overall survival (OS). We assessed the impact of obesity associated various factors on APL clinical course.
Methods
We retrospectively reviewed clinical records of the APL patients in our center since January 2008 to May 2019. We used Fisher’s exact test in univariate analysis, logistic regression in multivariate analysis, logrank test in survival analysis.
Results
51 patients were included in this study. The median age was 57 (range: 19-88), 24 females and 27 males. The median BMI was 23.1, 8 (15%) had BMI over 30 kg/m2. All patients were administered ATRA only or ATRA plus anthracycline based chemotherapy. 35 (68%) developed DIC at diagnosis, 18 (35%) developed DS by ATRA administration.47 (92%) achieved complete remission, median suvival was 1304 days (1-6608).9 (17%) experienced relapse.8 (15%) were died by bleeding, another cancer, organ failure. BMI over 30 kg/m2 was associated with high visceral and subcutaneous fat volume(P = 0.01, respectively). High triglyceride (TG) and LDL-cholesterol were independent of high BMI (P = 0.67, =0.54, respectively). In univariate and multivariate analysis, only high TG (over 150 mg/dl) was significantly associated with DIC (odds ratio (OR)= 10.6 (1.6-126.0), p = 0.004, OR = 11.6 (1.9-67.5), p = 0.006, respectively) and DS (OR = 7.31 (1.1-84.2), p = 0.02, OR = 7.7 (1.3-44.0), p = 0.02). BMI, TG, LDL, visceral or subcutaneous fat volume were not significantly affect with OS and DFS. DS onset or high white blood cell count were associated with inferior OS (P = 0.03) or PFS (P = 0.01).
Conclusions
High TG was a major risk factor of DIC and DS in APL treatment. It is possible that TG metabolic pathway will be linked to DIC and DS pathogenesis. Low fat diet or hyperlipidemia treatment may decrease DIC and DS progression.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
4526 - Long-term outcome of neoadjuvant tyrosine kinase inhibitors (TKI) in locally advanced dermatofibrosarcoma protuberans (DFSP)
Presenter: Jessica Beaziz
Session: Poster Display session 1
Resources:
Abstract
1214 - Neo-adjuvant (NA) Imatinib for gastrointestinal stromal tumours (GISTs): What is the optimal length of treatment?
Presenter: Tom Wilson
Session: Poster Display session 1
Resources:
Abstract
2690 - Gastrointestinal Stromal Tumours (GIST) in adolescents and young adults (AYA)
Presenter: Nikki Ijzerman
Session: Poster Display session 1
Resources:
Abstract
4558 - Radiomics improves response evaluation for desmoid tumors treated with chemotherapy
Presenter: Amandine Crombe
Session: Poster Display session 1
Resources:
Abstract
2751 - Radiomics of gastrointestinal stromal tumors; risk classification based on computed tomography images – a pilot study
Presenter: Milea Timbergen
Session: Poster Display session 1
Resources:
Abstract
2737 - Differentiating well-differentiated liposarcomas from lipomas using a radiomics approach
Presenter: Melissa Vos
Session: Poster Display session 1
Resources:
Abstract
1282 - The immune landscape of chondrosarcoma reveals an anti inflammatory environment
Presenter: Iseulys Richert
Session: Poster Display session 1
Resources:
Abstract
1572 - Impact of Immunotherapy and Targeted Therapy on Tumor Growth Rate in Sarcoma
Presenter: Esmail Al-ezzi
Session: Poster Display session 1
Resources:
Abstract
3414 - DNA methylation profiles of angiosarcoma subtypes.
Presenter: Marije Weidema
Session: Poster Display session 1
Resources:
Abstract
3411 - Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As and BTN3A1 in patients with metastatic gastrointestinal stromal tumors (mGISTs)
Presenter: Daniele Fanale
Session: Poster Display session 1
Resources:
Abstract